The Democratic Republic of the Congo (DRC) has received an initial allocation of 70,000 doses of the Ervebo Ebola vaccine to support the response to the ongoing Bundibugyo virus disease outbreak.
The World Health Organisation (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) disclosed this in a joint statement on Thursday.
The allocation followed a request by the DRC government last week for vaccines from the global Ebola virus disease vaccine stockpile managed by the International Coordinating Group on Vaccine Provision (ICG).
Of the 70,000 doses, 20,000 will be used in a Phase III clinical trial to assess whether Ervebo can protect against Bundibugyo virus, while the remaining 50,000 doses will be administered to frontline and health workers in line with recommendations by the WHO Strategic Advisory Group of Experts on Immunisation (SAGE).
Why the vaccine is being tested
